Merck Expands Vaccine Production with New State-of-the-Art Facility in North Carolina

Merck & Co. (MSD outside the U.S. and Canada) has just unveiled a brand-new, cutting-edge vaccine manufacturing facility at its site in Durham, North Carolina. The $1 billion expansion is a big step forward for the company as it works to boost vaccine production and invest in the future of U.S. pharmaceutical manufacturing.

This 225,000-square-foot facility isn’t just about adding more capacity—it’s about embracing the latest technology to improve efficiency and innovation. The site is equipped with advanced data analytics, generative AI, and even a digital twin—a virtual model of the manufacturing process that allows for testing and training without disrupting real-world operations.

Merck has been steadily increasing its investment in U.S. manufacturing, pouring more than $12 billion into capital projects since 2018. And they’re not stopping there—another $8 billion is planned for the next few years. This new facility is part of a broader push to strengthen domestic production and ensure the company can keep up with global demand for vaccines.

Sanat Chattopadhyay, who leads Merck’s Manufacturing Division, described the expansion as a major milestone in the company’s commitment to delivering life-saving vaccines. Meanwhile, Amanda Taylor, the plant manager in Durham, highlighted the dedication of the team behind the project, emphasizing how this investment reflects their hard work and expertise.

With this new facility, Merck is making it clear that it’s not just keeping up with the industry—it’s aiming to set new standards in pharmaceutical manufacturing.

Read the full press release here.